Formulary
Asfotase alfa: Indications, Dosing, Side Effects and Interactions
Asfotase alfa is a human recombinant tissue-nonspecific alkaline phosphatase that promotes mineralisation of the skeleton.
MedNext Academy | 3 min read
Asfotase alfa: Indications, Dosing, Side Effects and Interactions
Asfotase alfa is a human recombinant tissue-nonspecific alkaline phosphatase that promotes mineralisation of the skeleton.
Drug action
Asfotase alfa is a human recombinant tissue-nonspecific alkaline phosphatase that promotes mineralisation of the skeleton.
Indications and dose
**Paediatric-onset hypophosphatasia (initiated by a specialist)**
- **Adult** (By Subcutaneous Injection): 2 mg/kg 3 times a week, alternatively 1 mg/kg 6 times a week, dosing frequency depends on body-weight-consult product literature for further information.
**Paediatric-onset hypophosphatasia (initiated by a specialist) for asfotase alfa**
- **Neonate** (By subcutaneous injection): 2 mg/kg 3 times a week, alternatively 1 mg/kg 6 times a week, dosing frequency depends on body-weight-consult product literature for further information.
- **Child** (By subcutaneous injection): 2 mg/kg 3 times a week, alternatively 1 mg/kg 6 times a week, dosing frequency depends on body-weight-consult product literature for further information.
Cautions
Hypersensitivity reactions Cautions, further information Hypersensitivity reactions Reactions, including signs and symptoms consistent with anaphylaxis, have occurred within minutes of administration and can occur in patients on treatment for more than one year; if these reactions occur, manufacturer advises immediate discontinuation of treatment and initiation of appropriate medical treatment. For information on re-administration, consult product literature.
Side effects
Common or very common Bruising tendency; chills; cough; cutis laxa; fever; headache; hypersensitivity; hypocalcaemia; irritability; myalgia; nausea; nephrolithiasis; oral hypoaesthesia; pain; skin reactions; tachycardia; vasodilation; vomiting Side-effects, further information Injection-site reactions including hypertrophy, induration, skin discolouration, and cellulitis may occur, particularly in patients receiving treatment 6 times a week. Manufacturer advises rotation of injection sites to manage these reactions; interrupt treatment if severe reactions occur and administer appropriate medical therapy.
Interactions
**Other interactions (1):**
- Alkaline Phosphatase (ALP) is used as the detection reagent in many routine laboratory assays.
Pregnancy
Manufacturer advises avoid-no information available.
Breast feeding
Manufacturer advises avoid-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Asfotase alfa in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

